Literature DB >> 15504373

Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives.

Linda C Andrist1, Raquel D Arias, Deborah Nucatola, Andrew M Kaunitz, B Lynn Musselman, Suzanne Reiter, Jennifer Boulanger, Linda Dominguez, Steven Emmert.   

Abstract

The United States Food and Drug Administration approved a dedicated extended regimen of oral contraceptive (OC) pill in the fall of 2003. Few studies have explored how women or providers feel about menstrual suppression. This study describes women's and providers' attitudes toward menstrual suppression. A national sample of 1470 women and 512 providers responded to surveys asking about attitudes toward menstrual suppression. Seventy-eight percent of the women sample had never heard of menstrual suppression with OCs. Fifty-nine percent of women would be interested in not menstruating every month and one third would choose never to have a period. Only 7% of the providers thought it was physically necessary to have a period every month and 44% thought that menstrual suppression is a good idea. While 57% of providers said that their patients do not ask about extended use of OCs, 52% do prescribe them; patient request was the most common reason. Both samples thought that more research should be conducted and that the factors that would influence their decisions included long-term health effects, side effects, future fertility and cost. Results demonstrate that providers need to discuss this option with their patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504373     DOI: 10.1016/j.contraception.2004.06.008

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  12 in total

1.  Characteristics of scheduled bleeding manipulation with combined hormonal contraception in university students.

Authors:  Hannah Lakehomer; Paul F Kaplan; David G Wozniak; Christopher T Minson
Journal:  Contraception       Date:  2013-01-08       Impact factor: 3.375

Review 2.  Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.

Authors:  Alison Edelman; Elizabeth Micks; Maria F Gallo; Jeffrey T Jensen; David A Grimes
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

3.  Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.

Authors:  Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen
Journal:  J Fam Plann Reprod Health Care       Date:  2012-04

4.  New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control.

Authors:  Anita Nelson
Journal:  Int J Womens Health       Date:  2010-08-09

5.  The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg.

Authors:  Sheila Krishnan; Jessica Kiley
Journal:  Int J Womens Health       Date:  2010-08-10

6.  Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.

Authors:  Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen
Journal:  J Fam Plann Reprod Health Care       Date:  2012-04

Review 7.  The new extended-cycle levonorgestrel-ethinyl estradiol oral contraceptives.

Authors:  Rachel A Bonnema; Abby L Spencer
Journal:  Clin Med Insights Reprod Health       Date:  2011-09-19

8.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study.

Authors:  Stefanie Reif; Nelleke Snelder; Hartmut Blode
Journal:  J Fam Plann Reprod Health Care       Date:  2013-04

Review 10.  Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.

Authors:  Rossella E Nappi; Andrew M Kaunitz; Johannes Bitzer
Journal:  Eur J Contracept Reprod Health Care       Date:  2015-11-17       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.